Study of ALE.C04 in Patients With Head and Neck Cancer

Conditions: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma Interventions: Drug: ALE.C04; Drug: Pembrolizumab Sponsors: Alentis Therapeutics AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials